New Findings on Type and Amount of Tryptamine Derivatives in the Poison of the Colorado River Toad (Incilius alvarius) using LC-HR-QTOF-MS and LC-MS/MS



Institute of Forensic Medicine Forensic Toxicology

Nicole Zimmermann¹, Tobias Scholl², Johannes Penner³, Amy Autret⁴, Thomas Zander², Laura M. Huppertz¹, Volker Auwärter¹ and Merja A. Neukamm¹

¹Institute of Forensic Medicine, Medical Center, University of Freiburg, Germany

²ESA-Test GmbH, Eisenach, Germany

³Chair of Wildlife Ecology & Management, University of Freiburg, Germany

⁴Tucson Police Department, Crime Laboratory, Tucson, AZ, United States

Introduction and Aims

The Colorado River Toad (Incilius alvarius) is the only toad having an enzyme that converts bufotenin (= 5-hydroxy-N,N-dimethyltryptamine) into 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), an even more potent hallucinogen. That is why the toads' poison is smoked as a recreational drug.[1] To our knowledge, the skin of this toad has so far only been examined by Erspamer et al. in 1967 using paper chromatography and thin-layer chromatography. With these methods, 5-MeO-DMT has been described in estimated amounts of 50 to 150 mg/g, and 10 other indolalkyl derivatives have been found.^[2] We propose new approaches for the comprehensive analysis of the poison including the enrichment of compounds other than 5-MeO-DMT. Methods for LC-QToF-MS and LC-MS/MS analyses to detect both known and unknown substances in the toads' poison were developed. The LC-MS/MS method was then used to compare the concentrations of different tryptamine derivatives in zoo (captive kept) and wild toad poison samples, which to our knowledge has not been done before.




Methods

Sample Preparation

Sample collection

'Milking of the toads': Paratoid glands and the glands at the upper and lower legs of the toads were gently squeezed.






Enrichment of compounds other than 5-MeO-DMT

the large amounts of 5-MeO-DMT and subsequent chromatographic and MS system overload, further tryptamine derivatives could not be detected. For this reason, the following method was developed.

Fractionation using an analytical HPLC and the valve of the mass spectrometer; injection 20 x 10 µL



- Acetonitrile evaporated, remaining aqueous solution lyophilized
- Residue resuspended in 1 mL ethyl acetate, evaporated
- Residue dissolved in 20 µL mobile phase A/B 95/5

LC-QToF-MS and LC-MS/MS Analysis

- Quantitative analysis using LC-MS/MS
- Use of MRM transitions of reference standards and hypothetical MRM transitions of further substances
- Comparison of zoo and wild toad poison samples

Liquid Chromatography

- C18 column (100 mm \times 2.1 mm, 3 μ m)
- Mobile phase A: H₂O, 0.1 % HCOOH, 2 mmol/L NH₄+HCOO-, 1 % ACN
- Mobile phase B: ACN, 0.1 % HCOOH, 2 mmol/L NH₄+HCOO-
- Run time: 10 min
- Bruker Elute OLE HPLC for LC-QTOF-MS
- Dionex UltiMate® 3000 HPLC for LC-MS/MS

Mass Spectrometry

QToF

- Bruker Impact II™
- Ionization: ESI(+) Full Scan & bbCID

MS/MS

- Sciex QTRAP® 6500
- Ionization: ESI(+)
- MRM & EPI scan mode


Results and Discussion

Qualitative Analysis

Analytes included in the MRM method

- Reference standards available: 5-hydroxyindoleacetic acid, 5-OH-tryptophol, 5-MeO-DMT, 5-MeO-tryptamine, 5-methoxyindoleacetic acid, 5-OH-N-methyltryptamine, bufalin, bufotenin, DMT, marinobufagenin, serotonin, tryptophan
- With hypothetical MRM transitions: 5-OH-tryptophan, 5-MeO-DMT N-sulfate, 5-MeO-N-methyltryptamine, bufotenidin, bufotenin glucuronide, bufotenin N-sulfate, bufothionin, bufotoxin, bufoviridin, dehydrobufotenin, histamine, noradrenaline, hydroxylated MeO-DMT, di-OH-MeO-DMT, tri-OH-MeO-DMT, di-MeO-DMT, tri-MeO-DMT

Identified substances (standards available)



5-MeO-*N*-methyltryptamine tentatively identified




Figure: mass spectrum at 2.9 min; 5-MeO-N-methyltryptamine and fragments

- 5-MeO-*N*-methyltryptamine: isomer of bufotenin
- Fragments of 174.0909 Da and 162.0910 Da confirm the methoxy substitution of the indole ring
- No standard available, but also found by Erspamer et al.^[2]

Hydroxylated MeO-DMT tentatively identified by QToF-Screening





Figure: mass spectrum at 2.1 min; 4-OH-5-MeO-DMT (as one possible structure) and fragments

- MS fragmentation: α- and β- cleavage of the alkyl chain
- Fragments of 162,0550 and 190,0863 Da suggest that the indole ring and not the side chain is hydroxy and methoxy substituted.
- Exact position of the hydroxy and the methoxy group cannot be derived from the QToF measurement; several isomers with the following basic structure are possible:



- Assumption: position 5 is substituted with a hydroxy or methoxy group
- MRM transitions show two peaks at different retention times → at least two different isomers

No standards available





Figure: MRM transitions: 235/190 blue, 235/162 red

Quantitative Analysis

Comparison of zoo and wild toads' poison






Figure: Concentrations of tryptamines in zoo toad (Zoo Leipzig) and wild toad (Arizona, USA) poison samples in mg/g and µg/g, respectively. The mean concentrations are shown as dashed line. Concentrations above or below the calibration range

or lighter green. 5-MeO-tryptamine 5-OH-*N*bufotenin,

• 5-MeO-DMT: ca. 340 − 420 mg/g → high in comparison to 50 – 150 mg/g estimated by Erspamer et al.[2] for skin

methyltryptamine in wild toads than in zoo toads

Outlook

To verify that wild toad poison contains higher concentrations of certain tryptamine derivatives than zoo toad poison, more samples should be measured using the developed MRM method. The high concentration of 5-MeO-DMT compared to the literature shall also be verified by further measurements. By synthesis of all possible isomers of hydroxylated MeO-DMT, the tentative

Isomers in the toads' poison can be identified. The confirmation of 5-MeO-N-methyltryptamine in the extracts is also still pending. Further studies will include the vaporization of the poison with a special device to simulate consumption and to assess the content of tryptamine derivatives in smoke condensates by using the developed methodology.

Acknowledgements

The authors would like to thank Thüringer Aufbaubank, Erfurt, Germany for financial support. We thank F. Schmitt (Zoo Leipzig), R. Mangione & R. Riener (Haus des Meeres Wien), I. Koch & H. Aberle (Wilhelma Stuttgart), N. Kley (Welt der Gifte Greifswald), G. Talarico (Institute of Forensic Medicine Greifswald), M. Steige (Gifttierhaus Eimsheim) and C. Wilson & K. Condrey (Tucson Police Department, AZ, USA) for their help with sample collection.

References

[1] Weil A & Davis W (1994): Bufo alvarius: a potent hallucinogen of animal origin. Journal Ethnopharmacology 41: 1–8.

[2] Erspamer V et al. (1967): 5-Methoxy- and 5hydroxyindoles in the skin of Bufo alvarius. Biochemical Pharmacology 16: 1149–1164.

Contact

Merja A. Neukamm Institute of Forensic Medicine Albertstraße 9

79104 Freiburg, Germany merja.neukamm@uniklinik-freiburg.de

